The Department of Health and Social Care published its renewed Women's Health Strategy for England on 15 April 2026, setting out how the government intends to improve women's health and healthcare over the next ten years. The strategy builds on the original 2022 Women's Health Strategy and responds to the findings of the women's health ambassador's work, the results of the largest public engagement exercise in the department's history, and the persistent evidence of gender health gaps in diagnosis, treatment and research.
For community pharmacy, the renewed strategy carries several direct implications.
What the strategy says
The renewed Women's Health Strategy covers the full life course, from adolescence through to post-menopausal health and healthy ageing. Its core themes include:
- Reducing diagnostic delays for conditions such as endometriosis, polycystic ovary syndrome (PCOS), and autoimmune conditions that disproportionately affect women
- Improving access to contraception and reproductive health services, including through community pharmacy
- Strengthening menopause care, with a focus on ensuring that women can access hormone replacement therapy (HRT) without unnecessary barriers
- Addressing the gender data gap in clinical trials and health research
- Improving mental health support for perinatal depression, postnatal anxiety and the psychological impact of conditions such as endometriosis and infertility
- Tackling health inequalities, recognising that women from ethnic minority backgrounds, women with disabilities and women living in deprived areas face compounded disadvantage
Pharmacy-specific implications
The strategy does not contain a standalone pharmacy chapter, but several of its commitments directly affect community pharmacy practice:
Contraception access
The strategy reaffirms the government's commitment to expanding community pharmacy contraception services. Pharmacy-based oral contraception supply — already available through a locally commissioned service in many areas — is positioned as a key route to improving access, particularly for women who cannot easily attend GP appointments. The renewed strategy signals that national commissioning of pharmacy contraception is under active consideration.
For community pharmacists, this strengthens the case for maintaining and expanding contraception training. Pharmacists who already supply emergency contraception under Pharmacy First or local Patient Group Directions are well positioned to extend into routine oral contraception supply.
Menopause and HRT
The strategy addresses the well-documented difficulties women face in accessing HRT, including supply shortages, prescriber reluctance, and the cost of multiple HRT prescriptions. For pharmacy, this translates into:
- Continued demand for HRT counselling — explaining formulations, application techniques, and managing side effects
- Potential for pharmacy-led menopause consultations, building on the Pharmacy First model
- The need for stock management planning given ongoing supply variability for certain HRT products
Endometriosis and chronic pain
With an average diagnostic delay of approximately eight years for endometriosis in England, the strategy calls for earlier recognition and referral. Community pharmacists who see patients repeatedly purchasing over-the-counter analgesics for cyclical pelvic pain are uniquely placed to ask about red-flag symptoms and signpost to GP investigation. The strategy's emphasis on reducing diagnostic delay makes this a clinical priority for pharmacy teams.
Perinatal mental health
The strategy expands commitments on perinatal mental health support. Pharmacists dispensing antidepressants to pregnant or postnatal women should be aware of the strategy's emphasis on proactive follow-up — asking about side effects, checking adherence, and ensuring the patient has a clear pathway to their mental health team.
Health inequalities
The strategy's focus on women from disadvantaged backgrounds reinforces the role of community pharmacies in areas of high deprivation. PharmSee's analysis of the English pharmacy register shows that community pharmacies are disproportionately located in urban areas with higher deprivation indices, making them a natural access point for the populations the strategy aims to reach.
What this means for pharmacy teams
The renewed strategy is a policy signal, not a commissioning document. It does not create new funded services overnight. However, it establishes the direction of travel and gives pharmacy organisations — including the PSNC and local pharmaceutical committees — a framework for negotiating expanded women's health services in future commissioning rounds.
Practically, pharmacy teams should:
- Review current women's health service provision — are contraception, HRT counselling and menopause support services in place? If not, the strategy strengthens the case for commissioning them.
- Ensure CPD is up to date — the CPPE offers modules on contraception, menopause and perinatal mental health that align with the strategy's priorities.
- Be alert to diagnostic delay patterns — the strategy's emphasis on endometriosis, PCOS and autoimmune conditions means that pharmacy teams who recognise repeat presentations and signpost appropriately are delivering against a national priority.
Context: the broader pharmacy women's health landscape
PharmSee has published a series of articles on women's health topics relevant to pharmacy practice, including guides to emergency contraception, menopause and HRT, PCOS and endometriosis. The renewed strategy provides a policy anchor for the clinical content these guides address.
For pharmacists looking to explore women's health roles, the PharmSee jobs board lists vacancies across community, primary care and hospital settings. The PharmSee salary tool provides data on pharmacist earnings by region and specialty. The pharmacy directory maps over 13,000 community pharmacies across England, providing context for service planning in the areas the strategy aims to reach.